Search

Displaying results 1801 - 1810 of 8517 in total
  1. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  2. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magneti...

  3. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  4. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bil...

  5. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. … It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract.

  6. Drug

    Liothyronine

    go.drugbank.com/drugs/DB00279
    ApprovedInvestigationalVet approved

    [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]

  7. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]

  8. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  9. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  10. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    "bad cholesterol"), and very low-density lipoprotein (VLDL). … as "good cholesterol").